Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

56.80
-1.4100-2.42%
Pre-market: 56.42-0.3800-0.67%06:57 EDT
Volume:2.16M
Turnover:122.49M
Market Cap:10.99B
PE:378.67
High:58.23
Open:57.48
Low:56.13
Close:58.21
Loading ...

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks
·
04 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
04 Apr

RBC Lowers Price Target on Incyte to $64 From $68, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
03 Apr

BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters
·
01 Apr

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

Dow Jones
·
01 Apr

Shareholders in Incyte (NASDAQ:INCY) are in the red if they invested three years ago

Simply Wall St.
·
27 Mar

BRIEF-Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Reuters
·
26 Mar

Knight Therapeutics Announces Launch of Minjuvi® (Tafasitamab) in Mexico

THOMSON REUTERS
·
26 Mar

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
26 Mar

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX), Eli Lilly & Co (LLY) and Incyte (INCY)

TIPRANKS
·
25 Mar

Incyte Corp. Stock Rises Monday, Still Underperforms Market

Dow Jones
·
25 Mar

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating

MT Newswires Live
·
24 Mar

Incyte (INCY) was downgraded to a Hold Rating at William Blair

TIPRANKS
·
22 Mar

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts

TIPRANKS
·
22 Mar

Incyte Corp. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
22 Mar

BUZZ-US stocks weekly: March madness

Reuters
·
22 Mar

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

Reuters
·
22 Mar

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

StockStory
·
21 Mar

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Zacks
·
21 Mar